OGXI to present at ASCO in June
They'll have updated data on the 427 phase 2 prostate trial, according to Scott Cormack in today's "Future Leaders in the Biotech Industry" conference call. (This is also stated in slide 16 of the visual presentation, which is on OGXI's website.)
The only other news I caught was that they now have a name for the second-line P3 trial of 011 with cabazitaxel that's expected to begin later this year: the "Affinity" trial.
Their Q1 CC will be in early May.